AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of GBP 175.89 billion. The enterprise value is 195.87 billion.

Market Cap	175.89B
Enterprise Value	195.87B

Important Dates

The next estimated earnings date is Thursday, February 6, 2025.

Earnings Date	Feb 6, 2025
Ex-Dividend Date	Aug 9, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.22%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.54B

Valuation Ratios

The trailing PE ratio is 36.30.

PE Ratio	36.30
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.08, with an EV/FCF ratio of 27.37.

EV / Earnings	40.42
EV / Sales	5.13
EV / EBITDA	14.08
EV / EBIT	19.23
EV / FCF	27.37

Financial Position

The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.77.

Current Ratio	0.93
Quick Ratio	0.71
Debt / Equity	0.77
Debt / EBITDA	1.69
Debt / FCF	3.30
Interest Coverage	10.12

Financial Efficiency

Return on equity (ROE) is 16.66% and return on invested capital (ROIC) is 12.28%.

Return on Equity (ROE)	16.66%
Return on Assets (ROA)	8.50%
Return on Invested Capital (ROIC)	12.28%
Return on Capital Employed (ROCE)	17.31%
Revenue Per Employee	424,970
Profits Per Employee	53,903
Employee Count	89,900
Asset Turnover	0.51
Inventory Turnover	1.63

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +5.50% in the last 52 weeks. The beta is 0.18, so AstraZeneca's price volatility has been lower than the market average.

Beta (5Y)	0.18
52-Week Price Change	+5.50%
50-Day Moving Average	66.88
200-Day Moving Average	74.99
Relative Strength Index (RSI)	67.48
Average Volume (20 Days)	10,706

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of GBP 38.20 billion and earned 4.85 billion in profits. Earnings per share was 3.10.

Revenue	38.20B
Gross Profit	31.56B
Operating Income	10.20B
Pretax Income	5.91B
Net Income	4.85B
EBITDA	13.72B
EBIT	10.20B
Earnings Per Share (EPS)	3.10

Full Income Statement

Balance Sheet

The company has 3.68 billion in cash and 23.59 billion in debt, giving a net cash position of -19.91 billion.

Cash & Cash Equivalents	3.68B
Total Debt	23.59B
Net Cash	-19.91B
Net Cash Per Share	n/a
Equity (Book Value)	30.44B
Book Value Per Share	19.60
Working Capital	-1.32B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 8.46 billion and capital expenditures -1.30 billion, giving a free cash flow of 7.16 billion.

Operating Cash Flow	8.46B
Capital Expenditures	-1.30B
Free Cash Flow	7.16B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 82.61%, with operating and profit margins of 26.70% and 12.68%.

Gross Margin	82.61%
Operating Margin	26.70%
Pretax Margin	15.47%
Profit Margin	12.68%
EBITDA Margin	35.92%
EBIT Margin	26.70%
FCF Margin	18.73%

Dividends & Yields

This stock pays an annual dividend of 1.15, which amounts to a dividend yield of 1.61%.

Dividend Per Share	1.15
Dividend Yield	1.61%
Dividend Growth (YoY)	-1.11%
Years of Dividend Growth	n/a
Payout Ratio	71.25%
Buyback Yield	-0.22%
Shareholder Yield	1.38%
Earnings Yield	2.76%
FCF Yield	4.07%

Dividend Details

Stock Splits

The last stock split was on April 8, 1998. It was a forward split with a ratio of 3.

Last Split Date	Apr 8, 1998
Split Type	Forward
Split Ratio	3

Scores

AstraZeneca has an Altman Z-Score of 3.02.

Altman Z-Score	3.02
Piotroski F-Score	n/a